Scholarlink

<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a prevalent chronic liver condition lacking approved treatments, where the gut-liver axis is a key therapeutic target. This study aimed to identify novel probiotic strains and elucidate their strain-specific mechanisms by profiling their functional metabolites. We first investigated gut microbiota alterations in a human cohort (<i>n</i> = 151) and then evaluated six selected lactic acid bacteria strains in a Western diet-induced murine model of MASLD. Untargeted gas chromatography-time-of-flight mass spectrometry (GC-TOF MS) was employed to identify strain-specific metabolic signatures. The human study revealed significant gut dysbiosis in metabolic dysfunction–associated steatohepatitis (MASH) patients. In the animal model, probiotic administration significantly ameliorated hepatic steatosis and inflammation, and improved key serum markers. Crucially, metabolomic analysis demonstrated that each strain possesses a distinct metabolic phenotype; notably, <i>Bifidobacterium breve</i> CKDB002 showed a strong correlation with the antioxidant precursor cysteine, while <i>Pediococcus pentosaceus</i> KID7 was rich in various amino acids. Our findings demonstrate that specific probiotics can alleviate MASLD, and this therapeutic effect is strongly associated with their unique, strain-specific functional metabolites, providing a foundation for developing targeted, evidence-based therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Probiotic-Derived Strain-Specific Metabolites Ameliorate Metabolic Dysfunction–Associated Steatotic Liver Disease through Modulation of the Gut-Liver Axis

  • 期刊论文

  • 发表日期：

    2025年9月22日

查看全文
  • Sang Jun Yoon,
  • Jieun Choi,
  • Sung-Min Won,
  • Jeong Seok Yu,
  • Hee Young Kim,
  • Hyun Chae Joung,
  • In Gyu Park,
  • Jung A Eom,
  • Sang Hak Han,
  • Do Yup Lee,
  • Ki Tae Suk

摘要

Metabolic dysfunction–associated steatotic liver disease (MASLD) is a prevalent chronic liver condition lacking approved treatments, where the gut-liver axis is a key therapeutic target. This study aimed to identify novel probiotic strains and elucidate their strain-specific mechanisms by profiling their functional metabolites. We first investigated gut microbiota alterations in a human cohort (n = 151) and then evaluated six selected lactic acid bacteria strains in a Western diet-induced murine model of MASLD. Untargeted gas chromatography-time-of-flight mass spectrometry (GC-TOF MS) was employed to identify strain-specific metabolic signatures. The human study revealed significant gut dysbiosis in metabolic dysfunction–associated steatohepatitis (MASH) patients. In the animal model, probiotic administration significantly ameliorated hepatic steatosis and inflammation, and improved key serum markers. Crucially, metabolomic analysis demonstrated that each strain possesses a distinct metabolic phenotype; notably, Bifidobacterium breve CKDB002 showed a strong correlation with the antioxidant precursor cysteine, while Pediococcus pentosaceus KID7 was rich in various amino acids. Our findings demonstrate that specific probiotics can alleviate MASLD, and this therapeutic effect is strongly associated with their unique, strain-specific functional metabolites, providing a foundation for developing targeted, evidence-based therapies.